| INTRODUCTION
Successful treatment of canine lymphoma involves multi-agent chemotherapy protocols. A commonly used protocol consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has a reported response rate approaching 90%. T-cell phenotype for lymphoma has been shown to be a poor prognostic indicator in a number of studies. [1] [2] [3] [4] [5] [6] [7] [8] [9] Dogs with T-cell lymphoma have had decreased response rates to chemotherapy, with reduced remission times and overall survival times (OSTs), when compared with dogs with B-cell phenotype. 1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Duration of first remission for dogs with T-cell lymphoma has been previously reported as being between 1.7 and 6.3 months and overall survival of 4 to 9 months, which is greatly reduced compared to the 5 to 11 months and 11 to 13 months respectively, reported for dogs with B-cell lymphoma. 3, 5, 6, 9, 12 Alternative protocols for both naive and refractory large cell lymphoma have been investigated in dogs. Mechlorethamine, vincristine, prednisolone and procarbazine (MOPP) protocol has been used in the treatment of humans with both Hodgkin's and non-Hodgkin's lymphoma. 14 A MOPP protocol has also been investigated for dogs with relapsed/refractory lymphoma as well as a first-line treatment in combination with l-asparaginase. 9, 15 This combination chemotherapy protocol showed a high overall response rate as a first-line treatment but concurrently, a high rate of toxicity. Mechlorethamine is unavailable for veterinary use in some countries and so alternatives to this alkylating agent have also been investigated. Carmustine has been used as a substitute for mechlorethamine (BOPP protocol) for relapsed lymphoma with a reported 50% response rate and a concurrently high rate of toxicity. 15 Lomustine, vincristine, procarbazine and prednisolone combination protocol (LOPP) has been previously evaluated as an alternative to MOPP as a rescue protocol for canine lymphoma. 15, 16 These studies report overall response rates of between 52% and 61% in a relapse setting for both B and T phenotypes, but with high rates of toxicity. 15, 16 The purpose of this retrospective study was to evaluate the response rate and toxicity of a modified LOPP chemotherapy protocol as first-line therapy for the treatment of T-cell lymphoma in dogs. 
| MATERIALS AND METHODS

| Study population
| Treatment
Dogs treated in this study received injectable chemotherapy treatment only at the author's institution and so were evaluated with physical examination and haematology and biochemistry every 14 days. This LOPP protocol differed to protocol previously described and used for relapsed disease, the timing of the lomustine compared to the administration of vincristine was on consecutive days instead of the same day and the dose interval between vincristine doses was increased from 7 days to 14 days. 15 Lomustine, procarbazine and prednisolone was dispensed to the owners and its administration was performed in the patients' home. Both FDA-approved and compounded formulations of lomustine and procarbazine were used during the study, this was determined by drug availability and patient size.
| Response
All responses were classified according to the VCOG consensus statement for lymphoma. 18 A complete remission (CR) was considered a resolution of all clinically detectable disease. A designation of no response (NR) or partial response (PR) was determined based on the clinician's measurements and assessment in the medical record.
| Toxicity
Toxicity was determined through evaluation of clinical records and haematology and biochemical analysis performed at each patient visit.
Owners were provided a questionnaire at the time of each visit and were asked to report any observed side effects noted since the previous visit. The severity, duration and necessity for treatment for these side effects was determined by the clinician assessing the patient for that visit and toxicity was graded and recorded in the clinical record. Haematologic and biochemical parameters were assessed prior to the start of each cycle and a complete blood count was performed 7 days after the first lomustine administration, or at any time side effects were noted.
| Statistical analysis
Complete and PR rates were defined as the number of dogs experiencing respective remissions compared to the total number of dogs treated. Disease-free interval (DFI) was defined as the time from first documented remission until relapse, dogs were censored if they did not relapse or received autologous bone marrow transplantation after completion of chemotherapy. OST was defined as the time between first treatment and death. Dogs were censored from overall survival if they were still in remission and alive at the time of analysis.
Kaplan-Meier calculations were performed for both DFI and OST.
Dogs lost to follow-up were censored at the last date of contact.
Kaplan-Meier curves were created for categorical variables and for continuous variables categorized by median values (eg, age < 7.5 years and ≥ 7.5 years). Separate Cox proportional hazard analyses were performed to assess the effect of the body weight, hypercalcaemia, administration of l-asparaginase, thrombocytopenia, stage and substage on DFI and OST while accounting for the potential confounding variables of age and sex. Variables significant at .5 on bivariate analyses were entered into a multivariate model followed by a backwards stepwise protocol. The significance of each explanatory variable was tested using the Wald test. Explanatory variables that
were not statistically significant were removed from the model one at a time, beginning with the least significant. A P-value ≤.05 was considered statistically significant.
3 | RESULTS
| Treatment
Thirty-one dogs were included in this study. All dogs were treated with a modified LOPP protocol (Table 1) , which included l-asparaginase as part of induction in 13 of 31 dogs. Dogs in this study received an average of 6 cycles (range 2-16) with the intended protocol consisting of 6 cycles over a total of 24 weeks. Twentythree dogs (74%) completed the intended LOPP protocol.
| Patient characteristics
Median age was 7 years (range 3-13 years). Breeds represented were cross breed (6) Boxer (2) 
| Treatment response/toxicity, survival and prognostic factors
The overall response rate in this population of dogs was 97%.
Twenty-eight out of 31 (90%) of dogs were assessed to have had a CR to LOPP chemotherapy. Two dogs (7%) were assessed as having a PR, while 1 dog had NR (3%). Of the 30 dogs that had a response to the LOPP protocol, the median DFI was 176 days (range 0-1745).
Nine dogs (29%) remained in remission and 1 dog (3%) had received an autologous bone marrow transplant after obtaining a CR at the time of writing of this study. Their data was censored from DFI calculations, the range for DFI for these dogs was 102 to 1635 days.
Response, remission and survival times for all dogs in this study are summarized in Table 2 . A Kaplan-Meier curve for DFI, including 95% confidence intervals, is depicted in Figure 1 . Dogs with mediastinal and hepatic lymphoma were analysed separately and their data compared to dogs with multicentric lymphoma, this data are presented in Table 3 . There were 3 dogs with mediastinal lymphoma and 1 dog with hepatic lymphoma that remained in remission at the time of writing and so their data was also not included in DFI analysis (at a follow-up time of range-range days).
The OST for all dogs in this study was 323 days (range 51-1758).
Twenty-one dogs relapsed during the study period and 12 of these dogs (57%) received rescue chemotherapy. Rescue agents included a repeated LOPP protocol (6), l-asparaginase and doxorubicin (3), epirubicin and chlorambucil (1), epirubicin alone (1) and doxorubicin alone (1). Ten dogs were alive at the end of the study period, with the longest survivor being at 1696 days since diagnosis. The 1-and 2-year survival rates for dogs treated with LOPP chemotherapy were 39% and 25%, respectively. No deaths in the study population of dogs were confirmed to be because of causes unrelated to their lymphoma. A Kaplan-Meier curve for OST, including 95% confidence intervals, is depicted in Figure 2 .
Thirteen dogs (42%) experienced side effects during their chemotherapy protocol. The most frequently reported side effects involved 
Abbreviations: LOPP, lomustine, vincristine, procarbazine and prednisolone. Abbreviations: CR, complete remission; LOPP, lomustine, vincristine, procarbazine and prednisolone; PD, progressive disease; PR, partial response; SD, stable disease. Table 4 . 19 No grade V toxicities were reported in any dogs during this study.
FIGURE 1 Kaplan-Meier graph for disease-free interval (DFI)
Statistical analysis using Cox regression analysis testing failed to identify variables that were significantly associated with DFI or OST (Tables 5 and 6 ).
| DISCUSSION
The purpose of the study was to evaluate the use of LOPP chemotherapy in dogs with T-cell lymphoma. A secondary goal was to identify any prognostic factors for these dogs that were associated with DFI and OST. For dogs with T-cell lymphoma, we found that there was a high response rate (97%) but that the response was of limited duration (DFI 176 days) compared historically to that of B-cell lymphoma. OSTs were modestly improved compared to other reported protocols, with a lower reported overall toxicity rate (Table 4) .
Increased OSTs were seen when patients were treated with rescue chemotherapy of varying protocols. The use of rescue chemotherapy is dictated primarily by owner preference as well as financial constraints and so not all dogs routinely receive rescue chemotherapy.
No prognostic factors were significantly associated with DFI or OST in this study. Hypercalcaemia and substage were negative prognostic factors in previous studies on B-and T-cell lymphoma and may prove to be significant if a larger number of patients are studied.
In normal cells and tumour cells, one of the many mechanisms for cellular DNA repair includes the proteins O6-alkyltransferase (AGT) and O6-methylguanine-DNA methyltransferase (MGMT).
These proteins mediate a reaction with the O6-position of guanine in DNA, removing the lesion and leaving the guanine intact. Lomustine is a classic alkylating agent that acts by covalent binding of alkyl groups of DNA molecules, which results in reactive intermediates and DNA damage because of double-strand breaks. Procarbazine is a non-classic alkylating agent that requires metabolic activation and results in methylation of nucleic acids. Neoplastic T lymphocytes have been found to contain very low levels of the AGT and MGMT proteins, which make alkylating agents a good choice for treatment as these cells are often unable to effectively repair DNA damaged caused by alkylation or methylation. 20, 21 The hypothesis behind using a chemotherapy protocol that was alkylating agent rich was that T lymphocytes would have a higher response rate to these drugs due to inefficient DNA repair, and this was demonstrated by the high ORR of 97% in this study group. The comparable DFI and OST to other multi-agent protocols could be due to the acquisition of cellular resistance, likely influenced by an increased capacity to repair alkylated lesions through an upregulation of AGT or MGMT repair protein production and efficacy.
The LOPP protocol used in this study differed to the previously described protocol used in relapsed disease. 15 The dose interval between vincristine injections was increased from 7 days to 14 days.
The administration of lomustine occurred 1 day after vincristine administration instead of on the same day. These changes were instituted to minimize the haematologic and gastrointestinal toxicity to patients that resulted in only 9% of patients being able to receive the full doses of chemotherapy in the previous study. 15 This change to the dosing schedule for the LOPP protocol effectively reduced the overall toxicity rate of this protocol and 82% of patients received full doses of all the drugs in this modified LOPP protocol. This demonstrates a significant improvement to toxicity and patient tolerability compared to the original protocol.
Previously, three studies have reported on the response rates, In this study, CR and ORR were 88% and 95%, respectively; higher than the CR of 64% and ORR of 73% reported for the VELCAP-TSE study 22 and similar to the previously reported CR of 78% and ORR of 98% in the L-MOPP study, 9 and the CR of 88% and ORR of 96% of the L-CHOP study. 12 When compared to previous studies, this LOPP protocol had significantly lower reported toxicity, with side effects reported in only 42% of dogs with no stage V toxicities. The L-MOPP 9 and VELCAP-TSE 22 protocols had reported toxicity rates of 67% and 90% respectively, so it appears this is a better tolerated protocol. These comparisons have been summarized in Table 7 . 
| CONCLUSIONS
The modified LOPP chemotherapy protocol shows a high overall response rate and comparable DFI and OST for patients with T-cell lymphoma. This protocol exhibits an acceptable level of toxicity and high degree of owner compliance. The LOPP chemotherapy protocol is a viable treatment option for dogs with high-grade T-cell lymphoma. Abbreviation: LOPP, lomustine, vincristine, procarbazine and prednisolone. Abbreviation: LOPP, lomustine, vincristine, procarbazine and prednisolone. Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine and prednisolone; DFI, disease-free interval; MOPP, mechlorethamine, vincristine, prednisolone and procarbazine; ORR, overall response rate; OST, overall survival time; VELCAP-TSE, vincristine, l-asparaginase, cyclophosphamide, doxorubicin, lomusine, actinomycin, procarbazine and prednisolone.
